Medical Oncology

Gastrointestinal Cancers   

Questions discussed in this category


Nivo 3 + Ipi 1 Q2W x3 then Nivo alone? Or Nivo 3 Q2W & Ipi 1 Q6W until POD or toxicity? Or other?

Are there factors which would make you more likely to use atezo/bev vs durva/treme vs TKI?

When using hypofractionated RT (i.e., 67.5 Gy in 15 fractions), can chemotherapy be delivered concurrently?  Options for systemic therapy in NCC...

Would portal hypertensive gastropathy or colopathy sway you away from using it?

Given the recent update from the NAPOLI-3 trial presented at GI ASCO 2023, the two regimens appear to have similar OS.

For example, if mass is ulcerated and cannot be excised with polypectomy? Would you ever consider radiation and chemotherapy?

Current NCCN guidelines do not include adjuvant chemotherapy for patients treated in this fashion; however, in the PROSPECT trial itself, an additiona...

This would apply to gynecologic and GI cancers as well. And as long as the patient's partner is within the recommend age of <45 yo

There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?

And is there any role in utilizing FGFR2 inhibitors in first line setting? The PROOF trial utilizing Infigratinib in first line was stopped after the...

Would you wait until bowel symptoms are controlled or ever pursue diversion before starting treatment?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

Do you continue atezo alone if responding or switch to an alternative therapy such as dual IO or TKI? What about if the patient were experiencing subt...

Do you find that starting with chemoradiation increases the risk of complete obstruction secondary to transient tumor inflammation, or do you favor st...

Would you use nivolumab or a taxane? Is the data from the ATTRACTION-3 trial with an all-Asian patient population applicable to practice to the US pop...

For instance, do you factor availability of RNAseq, inclusion of normal blood controls, and QNS rates into your decision?

Especially as the study was done before the adoption of total neoadjuvant therapy

Would you only give three cycles with radiation, or are you adding two more cycles of FOLFOX afterwards?

Does DOTATATE scan results/burden of disease change your preference?

Would you offer single agent immunotherapy or chemo-immunotherapy with gem/cis durva/pembro?

Would you approach with curative intent with locoregional treatment or systemic treatment alone?

Would you treat both at the same time? Does one need to be prioritized over the other? Does Xeloda have any efficacy against Merkel cell cancer? How...

Would you offer as first line treatment mitomycin/5FU with radiation or single agent immunotherapy?

Will the results of the recently published randomized comparison of proton beam therapy (PBT) vs. transarterial chemoembolization (TACE) change the wa...

Is there a potential role for concurrent radiation therapy? What if the tumor is BRAF mutated?

Is there any data to support the use of immune checkpoint inhibitors either preoperatively or even definitively, similar to rectal or gastric?

Since there is no overlap between chemo regimens for these cancers, how would you sequence treatment? 

What systemic therapy is most appropriate, how would you sequence, and what RT dose fractionation would you use?

Exploratory analysis of the MAGIC trial suggested perioperative chemotherapy was detrimental in this subset of patients. Has availability of IO altere...

And is it different when using pembrolizumab or a combination of ipilimumab/nivolumab?

Do you use the same high risk factors as adenocarcinoma when deciding on adjuvant treatment for early stage disease?

Please specify how your institution is allocating resources now or will be soon.

> 30s, female with metastatic colon cancer. Presented with a headache. Metastatic hemorrhagic mets per MRI 10/2022. Had radiation. Kras mutated, Br...

Given the published results of the PRODIGE 23 trial where FOLFORINOX was used neoadjuvantly with FOLFOX post-op

Dose-escalation RT trials have had mixed results in the past for advanced rectal cancer, while in the early rectal stage there is a tendency towards a...

How do you weigh definitive chemoRT vs minimally invasive surgical approach with neoadjuvant chemo followed by transanal excision, in light of results...

Would sidedness matter? Do you use ctDNA assays to evaluate for acquired RAS mutations to guide this decision?

Would you advocate for a targeted gene approach or a fully comprehensive NGS panel?

Would your recommendation change in a patient having pain from disease and you wanted a quick response?

E.g. loss of PMS2 expression by IHC only but MSI stable by PCR.

For example, concerning throbocytopenia or neutropenia during anal cancer treatment with concurrent mitomycin/5FU, or other pelvic malignancies treate...

Specifically, would you consider either neoadjuvant or adjuvant immunotherapy in this setting, or only after recurrence?

Given that pembrolizumab/trastuzumab with chemotherapy is new SOC for metastatic disease, how would you approach those with recent fluoropyrimidine + ...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

If the patient had PSC and baseline atrophy preventing brachytherapy boost (received SBRT boost instead), would this change your threshold for stentin...

Patients with deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H) harbor high tumor mutational burden which tends to have fav...

Patients with gastric cancer can acquire new targetable mutations on progression. This could aid in additional treatment options in this group which t...

What other molecular tests do you routinely order on such tumors?

NCCN discusses targeted therapies (Everolimus) but also Temodar / Xeloda combination.

If so, what dose-fractionation regimen do you utilize? What are your target volumes?

If so, what assay would you use in this population? Do we have data on TMB/PDL1 status of long-term survivors?

I.E., can a patient with a questionable 5 mm node (MRI T2N1) which is negative on pathology after short course radiation be staged T2N0 and receive no...

No actionable genetic alterations were identified for this patient. Would you consider FOLFOX + durva, or even single-agent durva?

For nodes just inferior to the celiac/SMA axis and no other distant metastatic disease? Stage is formally M1, but just barely. The patient is otherwis...

TOPAZ-1 trial allowed for up to 8 cycles of gem/cis. Were there differences in chemotherapy duration/# cycles between treatment groups? Does use of du...

No preop therapy; dMMR in poorly cohesive and mucinous carcinoma component, pMMR in tubular adenocarcinoma component

What contraindications or concerns do you have in this scenario beyond assessing the Child Pugh Score?

C diff infection ruled out and CT abdomen pelvis shows diffuse enterocolitis extending far beyond the bowel-sparing IMRT radiotherapy field. 

Is there a difference in efficacy if dose is given later point during the course of therapy?

How would you balance the OS benefit from TOPAZ-1 with the risks of immunotherapy in this or other high-risk populations?

How do you sequence systemic treatment options for in patients with Child's Pugh B (or greater) in context of IMbrave150 and HIMALAYA? When do you in...

Is data sufficient to adopt this as the new standard of care? Can you comment on the reported regional and race-based variations in outcomes?  ...

Do you proceed with chemotherapy alone, neoadjuvant chemoRT, or definitive chemoRT? How do you communicate treatment intent to the patient?

Would a negative dotatate PET change management for a patient for whom you were planning to start SSAs?

For example, portion is seen above and below the mesorectal fascia. Do you feel comfortable treating as colon cancer with surgery upfront?

Would you extrapolate from the DESTINY-CRC01 study, even though RAS/RAF mutations were excluded?

Patient with initially stage IIIC right sided colon cancer s/p resection found to have metastatic disease prior to starting adjuvant therapy. MSI-H an...

Do you drop or adjust the temozolomide at any point, or rather continue to progression as long as temozolomide is well tolerated?

What would your approach be in a patient with a mid-esophageal squamous cell carcinoma treated with chemoradiation therapy followed by surgery, with P...

Would you consider the BEACON regimen (i.e., encorafenib/binimetinib + cetuximab) in this setting?

Which patients would you recommend active surveillance alone, a less morbid procedure such as enucleation, or a Whipple surgery? How does age influenc...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

If so, how many cycles would you give? Both the MAGIC and FLOT trials showed difficulty with administering adjuvant chemotherapy.

Would you give trastuzumab every 2 or 3 weeks, pembrolizumab every 3 or 6 weeks?

Would you consider gem+Abraxane to avoid FOLFIRINOX toxicity in a small, node-negative tumor?

Residual GEJ mass and progression in local lymph nodes after carbo+taxol chemoRT without distant metastases.

Is it necessary to test CPS given the FDA approvals are not contingent on CPS %?  If you do test, do you check 28-8 (nivolumab), 22C3 (pembroliz...

Would you use reduced dose chemoimmunotherapy, single agent chemotherapy, or single agent immunotherapy if the patient is unlikely to tolerate full do...

Do you view CPS < 1% or 1-4% separately? Do you view the incremental benefit of adding immunotherapy still advantageous given relatively poor outco...

Do you go by FDA approval alone, or incorporate other data into your treatment decisions?  How do you view updated recent presentation of CM-649 ...

What combination of fluoropyrimidine, PD-1 inhibitor, or trastuzumab do you use?

Are there contraindications to drugs like oxaliplatin or abraxane? Does chronicity or severity of the patient's underlying symptoms play a role in yo...

KEYNOTE 811 showed improved response rate with the addition of pembrolizumab, but very few patients in this study had low PDL1.

Given multidisciplinary discussion has occurred and SBRT has been agreed upon as local therapy, how do you approach the presence of moderate/significa...

Would you always offer an FGFR inhibitor as second line therapy in these patients instead of a second line chemotherapy regimen?

If an older patient is only fit enough for single agent fluoropyrimidine therapy, would you prefer to give this neoadjuvantly or adjuvantly?

Would you ever consider adjuvant chemotherapy rather than adjuvant immunotherapy after the publication of the CM-577 results? If so, in which pop...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

Pathology details: 75% high grade large cell neuroendocrine tumor of the cecum (20-30 mitoses per 10 hpf, Ki67 75%) and 25% adenocarcinoma. Patient ha...

G1 neuropathy and G3 neutropenia were observed with cycle 12 FOLFOX + bev. Would you reintroduce oxali at a lower dose or switch to irinotecan+EGFRi ...

NCCN recommends perioperative FLOT or FOLFOX vs. neoadjuvant chemoRT with Carboplatin/Paclitaxel or FOLFOX.Does CM-577 and the approval of nivolumab p...

If you had a patient with otherwise average risk stage 2 colon cancer but had signet ring or mucinous components to their pathology, would this sway y...

Of note - the tumor tissue biopsy NGS did not show KRAS or BRAF mutations. Microsatellite stable. Patient received first line FOLFOXIRI + Avastin .

For patients who have already undergone trimodality treatment, what time frame do you consider for adjuvant IO?

This involves the primary site responding but progression with new bone marrow involvement with resulting cytopenias.

Do you worry about fluoropyrimidine resistance with concurrent chemoRT? Is there any role for neoadjuvant immunotherapy?

Are there other treatment variations by clinical subsets (eg tumor location, histology, stage II vs III, other biomarkers) seen in CM577 or other data...

CheckMate 577 only included patients with R0 resection.For R1 resections, guidelines suggest observation vs re-resection only.  

Do you add on additional cycles of 5-FU/capecitabine to go beyond 3 months of treatment? Or would you stop at 3 months of therapy, dropping the oxalip...

Would the etiology of HCC affect your decision, e.g. non-viral hepatitis since less benefit was shown for this group in IMbrave150?

Do you treat with radiation therapy and what dose do you use? What dose do you accept to the duodenum?

Colleagues in surgery have raised concerns about post radiation effects in the pelvis with the ordering of short course RT->chemo ->surgery.

What determines duration of therapy in patients who achieve stable disease or no evidence of disease on imaging? Is there any role for radiation in t...

Ampullary carcinoma is not in the NCCN guidelines. Please address not only the role for therapy but the optimal regimen (i.e. Gem based, vs mFOLFIRINO...

Post-treatment PET/CT and MRI Pelvis at 3 months showed near resolution of iliac and inguinal lymphadenopathy but new avid retroperitoneal lymph nodes...

Colloid is a rare histologic subtype and considered to have more favorable outcomes compared with usual ductal adenocarcinoma, but no dedicated prospe...

Patients can develop sensory and motor symptoms such as paresthesias, jaw/facial pain and stiffness, cramping and twitching, ptosis and vision changes...

Has the recent approval of atezolizumab/bevacizumab impacted your decision making? 

Would you recommend radiation, systemic therapy alone, or chemoRT? What about if this recurrence occurred during or shortly after completion of adjuva...

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...

Does it differ in the curative vs palliative setting? Specifically thinking about adjuvant CAPOX in a patient with a BSA of 3. ~400 mg of oxaliplatin ...

Benefit of oxaliplatin in patients >70 years of age is not proven and only 5FU/capecitabine in a MSI-H tumor is of questionable efficacy. What woul...

Would you use a small cell regimen over a more traditional FOLFOX-esque approach?

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

If so, do you avoid pegfilgrastim given that <12 days will lapse between its administration and the next cycle?

If so, how long do you wait after surgery prior to imaging to avoid post-operative findings?

How do you assess the risk of complications from including bevacizumab vs the known benefits of including it with chemotherapy?

Would chemotherapy alone suffice? Repeat biopsy and EUS were negative for residual disease.

Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusi...

What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?

Or would you consider IO agent be given only after progression on platinum + fluoropyrimidine?

The patient went straight to gastrectomy for clinical T1 gastric adenocarcinoma, but post-op was up-graded to T4 disease.   Both ARTIST and Inte...

Would it make a difference if the VTE diagnosis occurs during bevacizumab therapy or whether it preceded the cancer diagnosis?

The upfront plan is to use a definitive radiation dose of 66 Gy. My reading supports the use of 5FU + cisplatin but another doctor is recommending FOL...

How would the sidedness of the tumor, BRAF, RAS,HER2 or MSI status affect your decision?

For a patient not on dialysis? Outside of single agent 5FU, all other standard chemotherapeutic options would be contraindicated for nephrotoxicity.&n...

Patients oftentimes have cardiac co-morbidities with requirement for anti-coagulation making TKIs, including Bevacizumab, difficult to dose. Would the...

When using short course RT, the NCCN guidelines currently recommend short course RT followed by chemotherapy, followed by surgery. Many surgeons are h...

Would you use dual agent chemotherapy such as FOLFIRI, combination of chemo with biologic- IRI/Cetux or all 3 drugs simultaneously? How would sidednes...

Upfront surgery vs neoadjuvant therapy? And if neoadjuvant therapy, which regimen? Patient has a good PS.

Quite often we encounter cholestatic hyperbilirubinemia, wherein GI and IR do not believe ERCP with stents or PTC will alleviate jaundice. If the pati...

Would you treat with typical small cell paradigms such as surgery followed by adjuvant platinum doublet +/- radiation vs definitive chemoradiation? Or...

Given that majority of benefit is derived from the capecitabine, would this be an acceptable option to decrease patient contact with the healthcare sy...

Would presence of features considered high risk in stage II sway your interpretation of the IDEA trial? 

With extensive use of NGS testing, it is commonplace to identify mutations that have no validated therapeutic intervention, but strong biologic signal...

In your experience, what approach has been successful to bridge to surgery?

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

Up to six cycles of treatment were given in the ABC02 trial.  Do you offer other treatments if you don't continue gem/cis beyond 24 weeks?

Of note, CLASSIC (Noh; Lancet Onc 2014) nor ARTIST (Lee; JCO 2012) evaluated other histologic subtypes, is the approach to treatment any different tha...

In light of the results of the ESPAC-4 trial, is combination gemcitabine plus capecitabine being considered over single agent gemcitabine for adjuvant...

If so, for what platelet count threshold and do you have a preference as to which agent?

In practice, does starting with chemoradiation followed by chemotherapy result in a significant delay in initiating chemotherapy or a patient's abilit...

Would the presence of peritoneal carcinomatosis change your treatment strategy? If Ki-67 <50%, would you avoid platinum based cytotoxics?

The German trial included patients with tumors up to 16cm from the anal verge, while the Swedish trial update found no local control benefit for tumor...

Given the variable and sometimes indolent disease course of these patients, as well as the absence of a clear overall survival benefit in the PROMID&n...

What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?

Is there a "best" way to approach treatment of the viral infection i.e concurrently with therapy, prior to therapy, delayed or post therapy? Does this...

If you do employ this strategy, are there a number of liver lesions (eg <4) or duration of response that guide your decision making?

Would you alter your SBRT dose? How long would you hold the VEGF inhibitor before and after? Does the primary matter (e.g. NSCLC vs. colorectal)?

A number of phase 2 trials support various combinations (e.g. gem/ox, cape/cis, cape/ox, 5-FU based) -- how do you decide either between these regimen...

The NCCN seems to make its recommendation based on extrapolation from colon cancer, but those patients are not treated with pre-op chemoRT.

How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?

Would presence of TP53 mutation weigh in on the offer of radiation? Would there be any change expected on the chemo regimen?

Would you consider adding trastuzumab to cis/gem in the first line? If not, would you consider adding Her2 directed therapy to FOLFIRI or FOLFOX in th...

Do you continue with FOLFIRI for a period and then switch to olaparib (and if so, when do you make that switch) or do you switch directly after FOLFIR...

Does the precise location of duodenal cancer even matter given that treatment would be 5FU/platinum based. Also with the knowledge of impact of sidedn...

On occasion, patients with locally advanced gastric cancer are poor candidates for FLOT-like chemotherapy. Should such patients be taken to surgery up...

Has the utility of BRAF in CRC expanded beyond guiding prognosis? Is there a role in non-metastatic CRC?

Patient characteristics would unarguably be a deciding factor, but outside of these how would you approach the situation?

There is some data on TMZ and 5FU based regimens, but convincing evidence is lacking. How would you approach this situation?

For instance, in borderline cases for neoadjuvant therapy (e.g. T2N1 disease), should both be obtained to increase accuracy?

There is increased stroke risk after 65 years of age with bevacizumab. Does that stop you from using it?

KEYNOTE-062 showed deep durable responses are possible with upfront pembro, specifically in the CPS >10 subset, with OS advantage when compare...

For those that do receive adjuvant therapy with stage II disease, we know magnitude of benefit to be lower.  If the decision is made to administe...

Do you offer perioperative chemo with metastectomy with an isolated liver metastasis? The RENAISSANCE/AIO-FLOT5 trial (PMID:30448343) is seeking to an...

For the first treatment day (during combined chemo/XRT courses), is it ok to give XRT first then send the patient for chemo or should the chemo be giv...

When 5FU is a backbone to so many regimens, when (if ever) do you consider re-challenging so as not to abandon an entire line of therapy?

This is specifically in regards to metastatic colon cancer with good disease control of disease on FOLFOX and preserved hepatic function.  

What would be the optimal sequence of surgery, radiation, and chemotherapy for this patient? This patient has an excellent performance status and...

What features would make you more likely to recommend radiation therapy with chemotherapy?

Does the lack of D2 dissection automatically necessitate adjuvant chemoradiation therapy (ie <5 LN obtained)? Would the presence of high risk facto...

I have seen favorable clinical trial reports on dasatinib for metastatic disease, but no data on possible adjuvant use.  NCCN guidelines suggest ...

For a patient with cT3-4N0 rectal cancer, does the dose of the previous RT affect your decision making (for example, 45 Gy to the pelvis with boo...

Currently, nivolumab is approved as a second line systemic therapy for patients with metastatic HCC with Child-Pugh (CP) A-B7 based on results fr...

How do you approach a decision to retry a previously failed therapy if patient does not wish to pursue a clinical trial? Does sidedness (left or right...

Do you offer chemotherapy upfront in all patients or only if borderline resectable/unresectable?  If you treat, what regimen do you use and how l...

What would you consider in the first and second line settings with intact MMR/MSI?

Would you switch chemotherapy regimens (i.e if the patient received FOLFOX/Avastin, change to FOLFIRI/Avastin)? Would you treat wuth immunotherapy per...

Would you consider repeating neoadjuvant chemo/RT? Does this, occurring in the context of Lynch Syndrome, change the treatment approach?

Does presence of intraperitoneal spread and solitary extraperitoneal visceral metastasis affect management?

Can you comment based on the results of PRODIGE 24 from ASCO 2018?   http://abstracts.asco.org/214/AbstView_214_218335.html

Do you start with 1250 mg/m2 BID and then dose reduce based on toxicities? Many studies across varied types of malignancies have shown good tolerabili...

If the patient has large, bulky nodes would you consider starting after chemotherapy for cytoreduction? Or otherwise consider replanning mid-treatment...

5FU/mitomycin C or 5FU/cisplatin? Is there any benefit of cisplatin in terms of skin toxicity?  

Would you consider referring the patient for HIPEC at some point in their treatment, possibly after giving adjuvant chemotherapy, especially if patien...

What factors dictate choice of observation versus 6 months of adjuvant peri-operative chemoradiation plus chemotherapy especially if patient did not r...

Taking into account the overlap between treatment regimens for esophageal and gastric cancers, in what clinical context might you feel comfortable tre...

NCCN lists CRT as category 1 but also lists chemotherapy alone as an option.  Is this decision based on discussion between surgeon and oncologist...

The abstract of the pooled meta-analysis is not definitive (JCO 35, 2017: suppl; abstr LBA1), and of the phase III trials (SCOT, TOSCA, Alliance/SWOG ...

If a patient with stage II or III colon adenocarcinoma who presents to your clinic 12-16 weeks after surgical resection do you give adjuvant chemother...

Does HER2 or PD1/PDL1 positivity change first line treatment (i.e. preferential enrollment on clinical trials) or do such patients still receiving sta...

The GTX (gemcitabine, docetaxel, capecitabine) regimen is listed as a category 2B recommendation in the NCCN guidelines- when would this be ...

Since immune check point inhibitors have been approved for GEJ and gastric cancer, would a distal esophogeal adenocarcinoma be considered GEJ or does ...

Would you consider subtotal gastrectomy vs medical therapy?

Most oncologists are comfortable offering FOLFOX for 1st line metastatic adenocarcinoma. Would you be comfortable offering FOLFOX to met. squamous eso...

Is there a change in approach over the past few years? Would there be a role for the 12-gene recurrence score?

NCCN puts "preferred" regimens but only category 1 is cisplatin and fluoropyrimidine. When would you use that regimen over FOLFOX?

In a patient who developed oligometastatic disease before completing adjuvant XELOX, what treatment(s) and duration of treatment would you recommend?

I have a few patients with kras braf mutation negative metastatic colon cancer treated with upfront FOLFOX- bev followed by 5FU-bev who had regression...

When PDL1 expression is negative, but IHC for mismatch repair expression is consistent with mismatch repair deficiency (MLH2, MSH2, and MSH6 expressed...

Regorafenib has been approved for patients with advanced HCC post-sorafenib, but the benefits are slight and toxicity substantial.  Nivolumab has...

Given recent FDA accelerated approval of pembrolizumab for MSI-H tumors regardless of site of origin, does it make sense to apply MSI testing, in...

If biopsy of the lesion is consistent with GI origin adenocarcinoma and there are no other sites of disease, would wedge resection followed by adjuvan...

Does your management differ if the hiccups are felt to be related to chemotherapy as opposed to the disease itself?

Tumor involves stomach, liver, and lymph nodes. Pathology is suspicious for sarcomatoid carcinoma, possibly sarcomatoid cholangiocarcinoma.

In LAP07's second randomization (capecitabine+54 Gy vs maintenance gemcitabine +/- erlotinib), 60% of unresectable pancreatic cancer patients who did ...

If a patient developed locoregional recurrence after initial chemoradiation, would resection of known disease followed by observation be preferred?

How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?

Would you use 5-FU and radiation alone? Would your management be different for loco-regional (curative) vs metastatic situations?

How do you weigh the recently presented/published data from the NETTER-1 and RADIANT-4 trials in your decision making?

Is salvage liver resection considered the next step in treatment for patients who may have resectable tumors after TACE?  If so, do specific tumo...

Is MRI being considered the primary mode of imaging in multidisciplinary tumor boards, especially in light of the results of the MERCURY trial (JCO 20...

In your practice, has tumor molecular profiling in pancreatic cancer led to the identification of any actionable targets for which a patient was put o...

Does the location of the pancreatic mass respective to the major vessels alter initial management (surgery, chemotherapy, radiation,  or some com...

Do you have a preference for Regorafenib or Lonsurf or do you refer to clinical trials immediately given the known low response rates to these drugs?&...

Would you consider HER-2 directed therapy (lapatinib-trastuzumab)? Does being KRAS-mutated affect your decision? 

Would taking the drug at a specific time point prior to their radiation appointment time to maximize blood levels of the drug be clinically beneficial...

Do you treat with standard of care therapy for microsatellite stable (MSS) colorectal cancers or pursue further work-up? Does this differ between adju...

Since some prior subset analyses have suggested that oxaliplatin may not improve outcomes of older patients with colon cancer in the adjuvant settin...

Does the recent Hopkins trial of pembrolizumab change your management of these patients?

Should oxaliplatin/capecitabine alone be the standard of care?

In a patient with an R0 resection, would you routinely recommend postop chemoradiation, since these patients were included in the MacDo...


Papers discussed in this category


N Engl J Med, 2006 Jul 6

The New England journal of medicine, 2001-09-06

BMC Cancer, 2015-07-21

Cancer, 2007-11-15

Cancer, 2015-04-01

JAMA, 2012 Jul 11

JAMA, 2008-03-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

International journal of radiation oncology, biology, physics, 2011-09-01

American journal of clinical oncology, 2011-02

International journal of radiation oncology, biology, physics, 2013-12-01

JAMA, 2007 Jan 17

Cancer, 1987 Jun 15

Ann Surg, 2007 Nov

Annals of surgical oncology, 2016-11

The Journal of thoracic and cardiovascular surgery, 2007 Aug

Lancet Oncol., 2017-09-01

J. Clin. Oncol., 2011 Mar 28

Cochrane Database Syst Rev, 2010 Mar 17

J Clin Oncol,

Curr Oncol, 2020 Dec 01

Lancet Oncol, 2020 Feb 26

J. Clin. Oncol.,

Lancet Gastroenterol Hepatol, 2019 Jul 29

J Clin Oncol, 2009 Oct 1

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019-09

N Engl J Med,

Pancreas, 2013-07

Eur J Radiol, 2006 Feb 21

Eur J Cancer, 2022 Sep 19

Lancet Oncol., 2015-09-01

JAMA oncology, 2018-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-01

Lancet Oncol., 2015 Dec 16

Lancet,

JAMA oncology, 2018-06-14

J. Clin. Oncol., 2019 Oct 08

The New England journal of medicine, 1985-06-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-11-01

J Can Assoc Radiol, 1981-09-01

J. Clin. Oncol., 1985-03-01

J. Natl. Cancer Inst., 1988-07-20

Ann. Oncol., 2008-09-01

Gastrointestinal cancer research : GCR, 2007-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-03-01

N Engl J Med, 2015 Jun 25

Lancet Oncol., 2016-06-01

J Cancer, 2016-01-01

The New England journal of medicine, 2011-02-10

The New England journal of medicine, 2011-02-10

Lancet (London, England), 2016-03-05

The New England journal of medicine, 2017-01-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-12-10

Lancet Oncol., 2013-05-01

Oncologist, 2016-12-01

Annals of surgical oncology, 2013-11

N. Engl. J. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-10

Dis. Colon Rectum, 2014-04-01

Clin Oncol (R Coll Radiol), 2017-04-01

Lancet, 2017-03-11

Can Fam Physician,

Journal of the National Comprehensive Cancer Network : JNCCN, 2014-04

The British journal of surgery, 2002-11

World journal of gastroenterology, 2010-06-28

Nat. Med., 2016-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01

The Lancet. Oncology, 2011-07

Lancet Oncol., 2015-10-01

Oncotarget, 2016-05-31

N. Engl. J. Med., 2004-06-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

Lancet Oncol., 2019 Mar 25

J. Clin. Oncol., 2019 Feb 01

Pancreas, 2010-08

Cancer, 2020 May 01

JAMA Oncol, 2022 Oct 01

Dig Liver Dis, 2021 May 12

Br. J. Cancer, 2016-08-09

The New England journal of medicine, 2005-05-05

Clin Cancer Res, 2020 Sep 1

Cancers (Basel), 2020 Jan 14

Clin Cancer Res, 2020 Jan 22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-12-20

Cancer medicine, 2016-12

N. Engl. J. Med., 2012-05-31

J. Clin. Oncol., 2016-08-10

Lancet Oncol., 2014-07-01

Ann. Oncol., 2014-07-01

J. Clin. Oncol., 2015-10-01

The Annals of thoracic surgery, 2010-09

J. Clin. Oncol., 2009-10-20

Journal of gastrointestinal oncology, 2016-08

The Lancet. Oncology, 2014-10

Lancet, 2010 Aug 19

N Engl J Med, 2020 May 29

J Clin Oncol, 2020 Mar 24

Radiat Oncol, 2014 May 29

Br. J. Cancer, 2014 Aug 28

J Gastrointest Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01

Lancet Oncol., 2007-09-01

Clin Colorectal Cancer, 2013 Jun 14

Lancet (London, England), 2007-12-15

J. Clin. Oncol., 2009 May 18

Cancer, 2016-01-15

Annals of surgical oncology, 2017-09

Eur J Surg Oncol, 2017 Sep 28

Eur. J. Nucl. Med. Mol. Imaging, 2016 Aug 18

Pancreas, 2016-11

J. Clin. Oncol.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-03-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-03-20

J Clin Oncol, 2007 Apr 1

J Clin Oncol, 2005 Apr 1

J. Clin. Oncol.,

Lancet,

NEJM Evidence, 2022 Jun 1

Science translational medicine, 2016-07-06

The Lancet. Oncology, 2017-09

Cancer, 2012-06-01

Cancer, 2016-07-01

International journal of radiation oncology, biology, physics, 2016-03-15

J Gastrointest Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-20

Br J Surg,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10

N. Engl. J. Med.,

JAMA Oncol, 2021 Jan 21

Oncol Lett, 2019 Sep 10

J. Clin. Oncol.,

The New England journal of medicine, 2002-10-17

Ann. Surg., 2007-11-01

N Engl J Med, 2021-04-01

J Clin Oncol, 2021 Apr 23

Lancet,

BMC Cancer, 2016 Jul 19

Lancet Oncol., 2013 Oct 11

Lancet (London, England), 2017-01-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-02-20

The British journal of radiology, 2017-08

J. Clin. Oncol., 2013 Nov 25

Advances in radiation oncology, 2018

BMJ, 2006 Sep 19

Eur. J. Cancer,

J Surg Oncol, 2021 Aug 01

Am J Surg Pathol, 2016 Jan

Am Soc Clin Oncol Educ Book, 2021 Mar

Clin Colon Rectal Surg, 2015 Dec

Oncology (Williston Park), 2021 Jun 23

International journal of radiation oncology, biology, physics, 2009-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-12-10

BMC Cancer, 2018 Jan 11

JAMA network open, 2020 Nov 02

J. Clin. Oncol.,

Lancet, 2015 Apr 07

JAMA, 2013 Oct 9

Clin Colorectal Cancer, 2018 Oct 10

Radiation oncology (London, England), 2011-09-28

JAMA surgery, 2019-05-29

J. Clin. Oncol., 2020 Feb 27

BMC cancer, 2017-12-28

JAMA Oncol,

Lancet Oncol., 2016 Jan 26

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-10-20

Cancer,

Eur J Surg Oncol,

Ann. Surg. Oncol., 2010 Sep 21

Clin Epidemiol, 2012 Nov 07

HPB : the official journal of the International Hepato Pancreato Biliary Association, 2016-03

Lancet Oncol., 2018 Apr 09

Lancet, 2019 Apr 11

Ann. Surg. Oncol., 2017 Mar 23

Annals of surgery, 2019-04-05

Nature, 2018-02-08

The Lancet. Oncology, 2019-04

Lancet Oncol., 2017 Nov 02

N. Engl. J. Med.,

Lancet, 2012 Jan 07

Lancet, 2018 Jun 04

Journal of gastrointestinal cancer, 2015-06

Eur. J. Cancer, 2017 May 11

Lancet Oncol., 2014 Feb 18

Ann. Surg.,

JAMA Oncol,

J Clin Oncol, 2012 Jan 20

J. Clin. Oncol., 2019 Sep 12

J Clin Oncol, 2022 Aug 15

Lancet Oncol, 2016 Oct 22

Sci Rep, 2018 Jun 06

Neuroendocrinology, 2019 Aug 21

Ann. Surg., 2019 Aug 30

J. Hepatol., 2017 Jan 23

The Journal of pathology, 2019-06

N. Engl. J. Med., 2019 Jun 02

Expert Opin Biol Ther, 2019 Mar 27

J. Clin. Oncol., 2019 Oct 14

Lancet Oncol., 2015 Aug 31

Lancet Oncol., 2020 Mar 09

Cancer,

J. Clin. Oncol., 2013 Aug 26

Cancer, 2011-09-01

International journal of radiation oncology, biology, physics, 2015-07-01

Cancer treatment reviews, 2017-02

Strahlenther Onkol, 2019 Feb 08

Radiother Oncol, 2018 Jul 09

Oncologist, 2019 Aug 07

JAMA, 2017-06-20

Annals of oncology : official journal of the European Society for Medical Oncology, 2017-08-01

Lancet Oncol, 2014 Jul 31

J Clin Oncol, 2022 Jun 06

J Clin Oncol, 2007 May 01

J. Clin. Oncol., 2003 Sep 08

N. Engl. J. Med., 2019 Sep 30

J. Hepatol., 2019 Apr 06

Ann. Surg.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-04-01

Curr Treat Options Oncol, 2019 Aug 19

J Oncol, 2019 Feb 20

Endokrynol Pol, 2019 Mar 07

J Hepatol, 2021 Nov 19

N Engl J Med, 2020 May 14

J Hepatol, 2021 Dec 11

Clinics in colon and rectal surgery, 2012-06

J. Clin. Oncol., 2019 May 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

Nature, 2017-08-10

Oncogene, 2018 Mar 15

Clin Cancer Res, 2019 Sep 12

JCO Precis Oncol, 2019 Aug 05

Gastroenterology, 2018 May 17

Clin. Gastroenterol. Hepatol., 2018 Nov 28

Hepatology (Baltimore, Md.), 2019-10

JAMA oncology, 2018-05-10

Eur. J. Cancer,

Sci Rep, 2017 Jul 04

JAMA oncology, 2019-06-01

J. Hepatol., 2016-05-01

Eur. J. Cancer, 2011-09-01

Lancet Gastroenterol Hepatol, 2017 Jun 23

Clin. Cancer Res., 2015 Oct 23

Invest New Drugs, 2015 Apr 12

J Hepatol, 2021 May 26

NEJM Evidence, 2022 June 6

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-10

Cancer, 2019-09-15

Int J Cancer, 2018 Apr 15

JAMA Oncol, 2019 Oct 31

Eur J Surg Oncol, 2014 Oct 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-11-01

N. Engl. J. Med.,

Br. J. Cancer,

Eur. J. Cancer, 2017-01-01

Int. J. Cancer, 2017 Jun 08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-20

J. Clin. Oncol., 2012-06-01

Annals of surgery, 1999-07

Journal of the National Cancer Institute, 2000-03-01

Diseases of the colon and rectum, 2009-04

Radiother Oncol, 2012 Nov 28

J Gastrointest Oncol,

Radiat Oncol J, 2019 Jun 30

Radiat Oncol, 2019 Jan 16

Radiat Oncol, 2014 Jul 22

Radiat Oncol, 2016 Sep 05

British journal of cancer, 2011-02-01

Anticancer Res.,

The New England journal of medicine, 1994-08-25

N. Engl. J. Med.,

Sci Rep, 2016 May 20

J. Clin. Oncol., 2019 Jan 17

Annals of surgical oncology, 2018-08

JAMA Netw Open, 2020 Feb 05

J. Clin. Oncol., 2015 Nov 16

Lancet Oncol., 2018 Oct 19

Semin. Oncol., 2017 Feb 11

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007-06-15

Seminars in oncology, 2003-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2003-07

Crit Rev Oncol Hematol, 2017 Mar 29

J. Clin. Oncol., 2020 Jan 24

Lancet Oncol., 2020 Mar 02

Clin. Cancer Res., 2018 Jun 27

Biosci. Rep.,

J Natl Compr Canc Netw,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-06-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

International journal of radiation oncology, biology, physics, 2007-02-01

Annals of surgical oncology, 2015-12

International journal of radiation oncology, biology, physics, 1993-12-01

International journal of radiation oncology, biology, physics, 2017-12-01

Clin Oncol (R Coll Radiol), 2017 Dec 07

J Contemp Brachytherapy, 2019 Feb 28

Eur J Gastroenterol Hepatol,

The Lancet. Oncology, 2015-08

Radiother Oncol, 2020 Mar 30

Ann. Surg., 2020 Mar 20

Lancet Oncol., 2017-03-01

Adv Radiat Oncol, 2020 Apr 22

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005-01

J. Nucl. Med.,

Neuroendocrinology, 2017 Apr 13

J Natl Compr Canc Netw,

Endocr. Relat. Cancer, 2017 Oct 24

Anticancer Res.,

JAMA Oncol, 2020 Dec 10

Cancer, 2018-06-01

Journal of the National Cancer Institute, 2018-11-01

Invest New Drugs, 2012 Oct 09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-07-10

JAMA oncology, 2019-05-09

JAMA oncology, 2019-05-09

J. Clin. Oncol., 2012 Aug 20

Gut, 2018 Feb 02

Ann. Oncol., 2019 Jun 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-01

Oncol Lett, 2015 Aug 11

International journal of radiation oncology, biology, physics, 2016-03-15

Cancer medicine, 2019-05

American journal of clinical oncology, 2019-03

Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03

Oncologist, 2020 Mar 10

Semin Diagn Pathol, 2016 Dec 23

Lancet Gastroenterol Hepatol, 2017-07-01

J. Clin. Oncol., 2020 Jun 12

J Surg Oncol, 2019 Jan 12

Ann. Surg. Oncol., 2015 Aug 05

Oncotarget, 2014-11-30

The New England journal of medicine, 2018-12-06

Lancet, 2019 Oct 04

Pancreas,

British journal of cancer, 2005-03-14

Case Rep Oncol, 2020 Jan 21

Lancet Oncol, 2020 Dec 07

Ann Oncol,

Lancet Oncol, 2021 Apr 13

J. Clin. Oncol., 2018 Dec 04

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2011-08

Am. J. Surg., 2013 Jul 01

J Surg Oncol, 2015 Oct 13

Nature, 2013 Aug 14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-10-01

Journal of the National Cancer Institute, 2012-02-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-04

Cancers (Basel), 2021 Jan 15

ESMO Open,

Lancet Oncol, 2020 Mar 20

J Clin Oncol,

British journal of cancer, 2011-06-07

JAMA oncology, 2018-09-01

Human pathology, 2019-06

Oncoimmunology, 2018

Clinical nuclear medicine, 2015-11

Surgery, 2016-01

J Nucl Med, 2012 Sep 17

Cardiovasc Intervent Radiol, 2019 Oct 23

Eur J Nucl Med Mol Imaging, 2018 Sep 28

Medicine (Baltimore),

Mod Pathol, 2017 Jan 06

Seminars in oncology, 2018-08

Endocrine-related cancer, 2016-09

Pancreas, 2017-07

JAMA Oncol, 2020 Apr 16

Pancreas, 2020 Jan

Surg Oncol Clin N Am, 2020 Oct 20

Scand J Gastroenterol, 2019 Aug 01

J Am Coll Surg, 2017 Jan 11

J Clin Oncol, 2018 Jun 07

Eur J Intern Med, 2008 Jun 10

Pancreas, 2010-08

Annals of surgical oncology, 2006-03

Neuroendocrinology, 2012 Feb 15

Neuroendocrinology, 2015 Sep 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-07

Gastroenterology clinics of North America, 2018-06

Eur J Cancer, 2015 Jun 08

J Clin Oncol, 2020 Dec 23

Lancet Oncol,

European journal of cancer (Oxford, England : 1990), 2019-01

Blood, 2020 Sep 10

Blood Adv,

The New England journal of medicine, 2018-07-05

Lancet (London, England), 2018-03-24

J Gastroenterol, 2019 Nov 12

Am Heart J, 2010 Sep 18

N Engl J Med,

The Lancet. Oncology, 2019-02

Hepatology, 2019 Oct 14

Cancer cell, 2018-05-14

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-07-01

Lancet Oncol, 2020 Sep 10

JAMA Oncol,

Cancer Discov, 2020 Nov 02

J Gastrointest Oncol,

Hum Mutat,

Ann. Surg. Oncol., 2017 May 30

Gut,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-20

British journal of cancer, 2016-03-29

Pancreatology, 2020 Oct 18

Lancet (London, England), 2016-02-06

European journal of cancer (Oxford, England : 1990), 2019-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20

Endocr Relat Cancer,

J Nucl Med, 2018 Aug 16

Eur J Nucl Med Mol Imaging, 2017 Sep 12

International journal of radiation oncology, biology, physics, 2018-09-01

European journal of cancer (Oxford, England : 1990), 2018-01

Seminars in radiation oncology, 1993-01

Radiother Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15

J Clin Oncol, 2016 Dec 28

CPT Pharmacometrics Syst Pharmacol, 2019 Nov 20

Lancet,

Future Oncol, 2021 Feb 03

N Engl J Med,

Gastric Cancer, 2013 Feb 28

J Clin Oncol, 2012 May 1

JAMA Oncol,

International journal of radiation oncology, biology, physics, 2011-01-01

Lancet (London, England), 2009-03-07

International journal of radiation oncology, biology, physics, 1989-02

Int J Radiat Oncol Biol Phys,

JAMA oncology, 2018-12-01

Cancer discovery, 2017-03

Ann Oncol, 2020 Nov 20

N Engl J Med, 2018 Mar 29

Hepatology (Baltimore, Md.), 2018-08

Radiology, 2018-06

Hepatology, 2021 Mar 19

J Clin Oncol, 2021 Jun 02

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-11

Int J Radiat Oncol Biol Phys, 2015 Jan 30

J Nucl Med, 2011 Jul 15

BMC Cancer, 2016 May 18

Eur J Cancer, 2021 Apr 29

Am J Transplant, 2016 Jun 09

Transplantation, 2021 Apr 27

Surgery, 2017 Jun 16

J Natl Cancer Inst,

Lancet Oncol, 2021 May 04

The New England journal of medicine, 2009-01-08

Am J Surg, 2020 Aug 16

Eur J Endocrinol, 2013 Apr 15

Jpn J Clin Oncol, 2013 Dec 22

Pancreas,

J Clin Endocrinol Metab,

J Endocrinol Invest, 2018 Jun 09

Br J Radiol, 2018 Mar 20

Eur J Nucl Med Mol Imaging, 2013 Sep 13

BMC Cancer, 2019 Aug 08

Scand J Gastroenterol, 2021 Jan 20

Int J Endocrinol, 2021 Jan 23

Cancer Treat Rev, 2020 Dec 22

JAMA Oncol,

Lancet, 2021 Jun 05

Human pathology, 2016-03

Curr Health Sci J, 2018 Jan 05

Clin Cancer Res, 2020 Mar 6

Int J Radiat Oncol Biol Phys, 2019 Dec 1

Pract Radiat Oncol, 2020 Oct 21

International journal of radiation oncology, biology, physics, 1988-02

Cancers (Basel), 2019 Jul 31

J Am Coll Surg, 2020 Jul 19

Cancer, 2018-02-15

Clin Colorectal Cancer, 2020 Dec 17

Cancer, 2016-09-01

N. Engl. J. Med.,

JAMA Oncol,

Ann Surg, 2021 Jul 16

Seminars in oncology, 2018-08

Pancreas, 2020 Aug

Neuroendocrinology, 2021 Feb 02

Annals of surgery, 2009-05

Annals of surgical oncology, 2019-04

PLoS One, 2021 Mar 26

Lancet Oncol., 2011 May 17

Eur J Surg Oncol, 2021 Jul 31

BMJ Open, 2021 Sep 24

The Lancet. Oncology, 2013-04

Ann Surg,

Int J Radiat Oncol Biol Phys, 2021 Aug 01

J Clin Oncol, 2022 Jan 27

Transpl Int, 2010 May 20

Eur J Surg Oncol,

World J Surg, 2019 Apr

J Surg Oncol, 2020 Sep 24

World J Gastrointest Surg, 2019 Jun 27

J Clin Oncol, 2021 Dec 03

Lancet Oncol, 2022 Jan 11

Lancet,

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Feb 19

Adv Radiat Oncol, 2020 Sep-Oct

Nature, 2021 Dec 15

Br J Cancer, 2021 Feb 03

Hepatogastroenterology, 2013 Jan 16

Medicine (Baltimore),

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-10

Brachytherapy, 2018

The New England journal of medicine, 2022 Feb 03

Oncologist, 2019 Apr

Eur J Cancer, 2022 Feb 21

Lancet Gastroenterol Hepatol, 2022 Feb 01

The New England journal of medicine, 2013-10-31

ESMO Open, 2021 Nov 24

Clin Cancer Res, 2017 Dec 29

Ann Pharmacother, 2021 Jul 20

Ann Transl Med,

Can Fam Physician,

World J Gastroenterol,

Ann Surg, 2021 Aug 13

Ann Surg,

J Clin Oncol, 2020 Mar 02

Nat Med, 2020 Apr 06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-10-10

JAMA oncology, 2018-03-01

J Clin Oncol, 2015 Nov 02

J Natl Cancer Inst, 2016 Feb 01

Lancet Oncol., 2015-10-01

Eur Respir J, 2017 Oct 12

N Engl J Med, 2022 Jun 05

N Engl J Med, 2022 Jun 04

Int J Radiat Oncol Biol Phys, 2022 Jul 04

J Natl Compr Canc Netw, 2021 Aug 24

J Neuroendocrinol, 2022 Apr 05

Neuroendocrinology, 2019 Sep 17

Pancreas,

JCO precision oncology, 2022 Jul

J Clin Oncol, 2022 Mar 22

Cancers (Basel), 2022 Mar 28

Ann Surg Oncol, 2021 Jul 01

Endocrine-related cancer, 2015-06

Eur J Cancer, 2013 Jan 23

Ann Oncol, 2012 Sep 11

Endocr Relat Cancer, 2012 Nov 06

J Cancer, 2014 Aug 01

Clin Cancer Res, 2019 Oct 31

Cancer Discov,

Pathol Res Pract, 2020 Apr 11

Oncologist, 2021 Aug 21

Endocr Connect,

ESMO Open, 2021 Apr 23

Oncologist, 2020 Sep 17

Br J Cancer, 2020 Mar 10

J Immunother Cancer,

International journal of radiation oncology, biology, physics, 1999-02-01

J Clin Oncol,

J Natl Compr Canc Netw, 2019 Jul 1

Future Oncol, 2020 Nov 10

J Clin Oncol, 2022 Nov 15

J Clin Oncol, 2022 Apr 28

N Engl J Med, 2022 Nov 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-06-01

Cancer, 2007-08-01

Journal of gastrointestinal oncology, 2017-12

Cardiooncology, 2019

Cardiol Clin, 2019 Aug 26

JACC CardioOncol, 2021 Mar 16

Clin Cancer Res, 2020 Aug 20

Cancer, 2019-01-01

HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017-07

JAMA Oncol, 2021 Dec 01

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007-11

Annals of surgery, 2010-03

Cancer, 2016-02-15

JAMA network open, 2024 Jan 02

International journal of clinical oncology, 2014

Cancer Epidemiol, 2021 Aug 04

Eur J Cancer, 2018 Jul 20

Adv Anat Pathol, 2020 May

Ann Oncol, 2022 Dec 20

Eur J Cancer, 2021 Nov 02

Oncologist, 2020 Dec 14

Mol Oncol, 2022 Jul 22

Advances in radiation oncology, 2016

Gastroenterology, 2012-07

Brachytherapy, 2018

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-05-01

Asia-Pacific journal of clinical oncology, 2020 Aug 05

Annals of surgical oncology, 2020 May 13

J Clin Oncol, 2014 Oct 06

Eur J Cancer, 2018 Aug 24

Gastric Cancer, 2022 Jan 11

J Cancer Res Clin Oncol, 2022 Aug 30

Oncologist, 2020 Oct 28

JAMA Dermatol, 2017 Jul 01

Clinics in colon and rectal surgery, 2019-05

J Gastrointest Oncol, 2020 Feb

Front Oncol, 2023 Feb 02

JAMA Oncol, 2019 Mar 01

Nat Med, 2022 Aug 01

Br J Cancer, 2020 Aug 31

Target Oncol, 2021 Oct 31

JAMA Oncol, 2021 Oct 01

Ann Oncol, 2019 Feb 01

Diseases of the colon and rectum, 2019 Jun

J Clin Oncol, 2022 Aug 18

JAMA Surg, 2019 Jan 01

The Lancet. Oncology, 2015-11

Journal of Cancer, 2010-06-28

Cancer Imaging, 2011 Oct 03

Lancet Oncol, 2020 Jan 31

Eur J Cancer, 2020 Sep 03

J Clin Oncol, 2006 Nov 01

J Clin Oncol, 2008 Sep 15

Ann Oncol, 2009 Jan 29

Int J Radiat Oncol Biol Phys, 2012 Jul 03

J Clin Oncol, 2023 Jan 05

Oncology, 2022 Oct 28

Human pathology, 2018-09

Pancreas, 2020 Oct

Dig Dis Sci, 2022 Jun

Ann Surg, 2010 Feb

Neuroendocrinology, 2016 Jan 06

Nat Med, 2023 Jan 16

The Journal of molecular diagnostics : JMD, 2008-07

Archives of pathology & laboratory medicine, 2018-04

Nat Med, 2015 Apr 20

Arch Pathol Lab Med, 2011 May

Ann Oncol, 2017 Jan 01

Cancer Sci, 2021 Jun 07

J Natl Cancer Inst, 2021 Feb 01

J Clin Oncol, 2019 Nov 04

Gut, 2020 Apr 29

J Clin Oncol, 2021 Oct 12

Nat Cancer, 2020 Aug 03

Cancers (Basel), 2021 Feb 21

J Neurooncol, 2017 Nov 23

Annals of surgery, 2006-12

Annals of surgical oncology, 2013-07

Annals of surgical oncology, 2010-01

Diseases of the colon and rectum, 1999-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-10

Dermatol Pract Concept, 2019 Jan 31

Clin Cancer Res, 2013 Jul 05

Journal of the National Cancer Institute, 2016-06

Pediatrics, 2014 Feb 02

N. Engl. J. Med.,

The Journal of urology, 2018-12

Br J Cancer, 2014 Apr 15

Cancer, 2011-06-15

Eur J Cancer, 2017 Nov 28

N. Engl. J. Med., 2019 Sep 28

Lancet Oncol, 2021 Jan 18

J Clin Oncol, 2021 Apr 19

J Clin Oncol, 2003 Jul 01

J Clin Oncol, 2019 Sep 26

Ann Surg, 2023 Jan 20

Ann Oncol, 2022 Oct 25

J Clin Oncol, 2023 Jun 04

N Engl J Med, 2023 Jun 04

N. Engl. J. Med., 2004-10-21

Ann Surg, 2020 Mar

Future Oncol, 2020 Apr 30

JAMA, 2019 Apr 16

Head Neck, 2016 Mar 29

The Lancet. Oncology, 2017-05

Lancet Oncol, 2023 Jun 02

Oncology (Williston Park), 2022 Feb 08

Insights Imaging, 2018 Nov 14

JAMA, 2021 Feb 16

Lancet (London, England), 2009-03-07

Ann Surg, 2011 Apr

JAMA Oncol, 2019 Jul 01

J Clin Oncol, 2023 Jun 19

Cancer, 2005-01-01

Cancer chemotherapy and pharmacology, 2011-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010 Sep 20

British journal of cancer, 2008 Sep 16

Cancer chemotherapy and pharmacology, 2009 Jan 14

Cancer, 2007 Sep 15

Annals of oncology : official journal of the European Society for Medical Oncology, 2013 Aug 23

Ann Surg Oncol, 2023 May 19

NEJM evidence, 2022 Jun 06

Clinical cancer research : an official journal of the American Association for Cancer Research, 2008-01-15

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013 Jan 29

Journal of geriatric oncology, 2020 Jun 21

Medical oncology (Northwood, London, England), 2018 May 31

Future oncology (London, England), 2022 May 10

Frontiers in oncology, 2023 Jun 29

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021 Dec 20

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2010 Oct

Cancer medicine, 2018-12

Oncology (Williston Park, N.Y.), 2018-01-15

Frontiers in oncology, 2023 Jun 08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Jan 09

Annals of oncology : official journal of the European Society for Medical Oncology, 2009 Jun 05

AJR Am J Roentgenol, 2020 Oct 21

J Natl Compr Canc Netw, 2022 Sep

Ann Surg Oncol, 2022 Mar

World journal of gastrointestinal surgery, 2023 Feb 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 15

Nature communications, 2023 Jun 07

Int J Radiat Oncol Biol Phys, 2019 Oct 1

Frontiers in oncology, 2020 Mar 24

International journal of radiation oncology, biology, physics, 2023 Apr 08

Cancer, 2023 Jul 28

N Engl J Med, 2022 Jun 03

Lancet (London, England), 2023 Feb 07

Gastrointestinal endoscopy, 2012-01

Gastrointestinal endoscopy, 2012 Feb

Cancer, 1989-03-15

Lancet (London, England), 2000 May 06

Therapeutic advances in medical oncology, 2017-02

Journal of geriatric oncology, 2023 Mar 22

The New England journal of medicine, 2021 Mar 25

The oncologist, 2022 Mar 11

Frontiers in oncology, 2022 Aug 24

Diseases of the colon and rectum, 1993-01

Cancer, 1976 Apr

Annals of oncology : official journal of the European Society for Medical Oncology, 2011 Apr 29

Digestion, 2018 Jun 05

British journal of cancer, 2016 Mar 15

Endocr Relat Cancer, 2023 May 1

JAMA oncology, 2021 Jun 01

Journal of gastrointestinal oncology, 2020 Aug

JAMA network open, 2023 Nov 01

The New England journal of medicine, 2023 Jun 04

Nature medicine, 2023 Sep 14

The New England journal of medicine, 2023 Oct 20

Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Oct 05

Lancet (London, England), 2009-10-24

N Engl J Med, 2022 Apr 11

The New England journal of medicine, 2023 Jun 03

The New England journal of medicine, 2023 Oct 21

JTO clinical and research reports, 2023 Aug 16

The New England journal of medicine, 2023 Oct 23

N Engl J Med, 2021 Jun 23

Future oncology (London, England), 2021 Jun 08

Cancer cell, 2021 Jun 17

The New England journal of medicine, 2023 Oct 22

The New England journal of medicine, 2023 Oct 21

Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Oct 11

The American surgeon, 2015 May

Nature medicine, 2008-09

Annals of oncology : official journal of the European Society for Medical Oncology, 2017-06-01

The Cochrane database of systematic reviews, 2015 Dec 10

Japanese journal of clinical oncology, 2002 Feb

British journal of cancer, 2019 Apr 24

The Lancet. Oncology, 2019 Sep 30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Oct 07

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019 Jul 23

BMC cancer, 2021 Nov 10

Cancer medicine, 2019 Jul 04

BMJ (Clinical research ed.), 2018 Sep 10

JAMA oncology, 2023 Dec 21

International journal of radiation oncology, biology, physics, 2024 Jan 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Mar 09

Seminars in oncology, 2006-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-04-01

Annals of surgical oncology, 2022 Oct 13

Scientific reports, 2021 Mar 18

Clinical colorectal cancer, 2020 Sep 09

Journal of neuroendocrinology, 2023 Apr 05

Journal of neuroendocrinology, 2023 Mar 16

Current oncology reports, 2023 Aug 22

American journal of clinical oncology, 2023 Dec 22

The oncologist, 2015 Jan 07

PloS one, 2023 Aug 10

Lancet (London, England), 2023 Dec 14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Oct 28

JAMA oncology, 2019 Nov 01

Radiographics : a review publication of the Radiological Society of North America, Inc, 2023 Mar

Cancers, 2020 Jun 13

Indian journal of surgical oncology, 2023 May 02

Scientific reports, 2023 May 31

Pract Radiat Oncol, 2021 Oct 21

Lancet (London, England), 2023 Apr 16

NEJM evidence, 2022 Jun 01

JAMA oncology, 2017-02-01

Nature medicine, 2024 Feb 12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-01-01